The Islamic Republic of Iran has made significant progress in its efforts to produce stable isotopes, a critical component of its nuclear energy program. Speaking at a recent event in Tehran, Mohammad Eslami, Iran’s Vice President and Head of the Atomic Energy Organization (AEOI), highlighted the importance of these isotopes in advancing health and safety.

Eslami mentioned that over the past two years, AEOI has developed programs to produce stable isotopes, with a particular focus on tellurium dioxide, a key ingredient in iodine-131. This radioactive isotope is essential for treating thyroid cancer, a condition that affects millions globally. The presentation of tellurium dioxide marks a milestone in AEOI’s efforts to achieve self-sufficiency in radiopharmaceutical production.

“Currently, the production of tellurium dioxide is at its final stage, and this achievement is a crucial step toward ensuring access to essential medical treatments for the Iranian people,” Eslami emphasized. He added that the next phase will involve mass production, meeting domestic needs and creating opportunities for exports.

The event also saw the introduction of new isotopes into AEOI’s agenda, reflecting its broader goals of innovation and self-reliance in the nuclear sector.

In summary, this move underscores Iran’s commitment to health and energy independence, marking a positive step toward reducing reliance on foreign supplies and improving the well-being of its citizens.